The present invention relates to allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and […]

The present invention relates to a hepcidin antagonist for use in the treatment of inflammatory diseases. TLR4-dependant intestinal hepcidin induces […]

Voltage-dependent calcium channels (Cav1) contribute to T-cell activation. The inventors previously showed that Th2 cells co-express Cav1.2 and Cav1.3 […]

Type I interferonopathies represent a subgroup of autoinflammatory diseases caused by mutations in genes associated with proteasome degradation or […]

The incidence of food allergy has dramatically increased over the last three decades in industrialized countries, now affecting more than 200 million […]

A growing number of patients presenting severe combined immunodeficiencies attributed to monoallelic RAC2 variants have been identified. The […]

The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect […]

NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor […]

The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells […]

Cytoablative treatments lead to severe damages on thymic epithelial cells (TECs), which result in delayed de novo thymopoïesis and a prolonged period […]